Completion of the first adult dose cohort, which received the lowest dose of HG-CT-1, represents a pivotal milestone in the Company's trial. If no dose-limiting toxicities are observed, Hemogenyx ...

TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

Schrödinger Inc (NASDAQ:SDGR) shares dropped 13.7% following the company’s announcement that it is discontinuing development ...

Investing.com -- Schrodinger Inc (NASDAQ:SDGR) stock plunged 13.7% after the company announced it is discontinuing the clinical development program for its CDC7 inhibitor SGR-2921, which was being ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Schrodinger discontinued its study of a potential treatment for acute myeloid leukemia or high-risk myelodysplastic syndromes, citing patient deaths linked to the treatment.

Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its ...

Schrodinger (SDGR) announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated ...